Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2010

View Archived Issues

Flibanserin improves HSDD symptoms in premenopausal women

Schering-Plough discloses new TNF-alpha production inhibitors

Biotie Therapies and Wyeth identify novel PDE inhibitors

Gruenenthal presents new bradykinin B1 receptor antagonists

UCB claims novel PI3K inhibitors

Diagnostic/prognostic gene expression signature identified for UCC

Regulus obtains license to microRNA-21 intellectual property

KB-001 shows clinical promise in P. aeruginosa infection

HRH1 gene SNP may predict response to OFC in depressed individuals

Gilead Sciences updates pipeline progress

Celgene discovers new TNF-alpha production inhibitors for cancer therapy

Aragen and Amorfix agree to co-develop cancer-targeting mAbs

FDA approves Photocure's Cysview for bladder cancer detection

German Health Agency sends official calendar for bilastine registration procedure

Cyberonics reports on postmarket VNS Therapy trial in depression

Synergy of ipilimumab and androgen ablation reported in prostate cancer

YM opens phase II nimotuzumab trial in patients with brain metastases from NSCLC

AstraZeneca and NIH's NIDDK collaborate to support DILIN

VaxGen to acquire diaDexus under revised merger agreement

Tesaro secures funds to acquire and develop cancer therapeutics

Noxxon Pharma raises funds for lead product development

ARCA launches phase I trial of GeoVax Labs' HIV vaccine

CytRx begins phase II bafetinib trial in B-cell chronic lymphocytic leukemia

Wyeth Europa notifies EMA of withdrawal of MAA for Brilence

Preclinical data demonstrate antileukemic effects of OXiGENE's OXi-4503

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...